NasdaqGS - Nasdaq Real Time Price USD
PepGen Inc. (PEPG)
1.5300
+0.0400
+(2.68%)
As of 1:45:25 PM EDT. Market Open.
Key Executives
Amounts are as of December 31, 2024 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. James G. McArthur Ph.D. | President, CEO, Treasurer, Secretary & Director | 850.67k | -- | 1962 |
| Mr. Noel P. Donnelly M.B.A. | Chief Financial Officer | 633.71k | -- | 1970 |
| Dr. Paul D. Streck M.B.A., M.D. | Executive VP and Head of Research & Development | 332.73k | -- | 1964 |
| Dr. Michael Gait Ph.D. | Founder & Scientific Advisory Board Member | -- | -- | -- |
| Ms. Emiko Bryant | Chief of Staff, HR & Operations | -- | -- | -- |
| Ms. Mary Beth DeLena J.D. | General Counsel & Secretary | -- | -- | 1968 |
| Dr. Hayley Parker Ph.D. | Senior Vice President of Global Regulatory Affairs | -- | -- | -- |
| Dr. Afsaneh Mohebbi Ph.D. | Senior VP of Portfolio and Program Management | -- | -- | -- |
| Mr. Kyle Breidenstine CPA, M.B.A. | VP of Finance & Controller | -- | -- | -- |
PepGen Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 79
Description
PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. Its lead product candidates comprise PGN-EDO51, an EDO peptide which is Phase 2 clinical trial to treat duchenne muscular dystrophy (DMD) patients that are amenable to an exon 51-skipping approach; PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and PGN-EDO53, which is in preclinical trial to treat duchenne muscular dystrophy. The company was founded in 2018 and is based in Boston, Massachusetts.
Corporate Governance
PepGen Inc.’s ISS Governance QualityScore as of May 1, 2025 is 7. The pillar scores are Audit: 8; Board: 5; Shareholder Rights: 8; Compensation: 8.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Upcoming Events
August 6, 2025 at 10:59 AM UTC - August 13, 2025 at 12:00 PM UTC
PepGen Inc. Earnings Date
Recent Events
Related Tickers
DSGN Design Therapeutics, Inc.
3.6400
+3.12%
GLUE Monte Rosa Therapeutics, Inc.
4.1500
+0.97%
CGEM Cullinan Therapeutics, Inc.
7.90
+2.46%
RLYB Rallybio Corporation
0.3498
+0.81%
ACRV Acrivon Therapeutics, Inc.
1.2650
+7.23%
ENVB Enveric Biosciences, Inc.
1.3500
-0.73%
TYRA Tyra Biosciences, Inc.
10.18
+5.17%
MLYS Mineralys Therapeutics, Inc.
16.61
+8.42%
HLVX HilleVax, Inc.
1.9900
+2.05%
EWTX Edgewise Therapeutics, Inc.
15.17
+2.53%